MiNK Therapeutics (INKT) to Release Quarterly Earnings on Friday

MiNK Therapeutics (NASDAQ:INKT) is anticipated to post its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($0.86) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Friday, November 14, 2025 at 8:30 AM ET.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.51). On average, analysts expect MiNK Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MiNK Therapeutics Trading Down 0.8%

NASDAQ INKT opened at $13.66 on Wednesday. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00. The stock has a market cap of $61.74 million, a PE ratio of -4.74 and a beta of 0.33. The stock’s 50 day moving average is $14.39 and its 200 day moving average is $12.76.

Analysts Set New Price Targets

A number of brokerages have issued reports on INKT. Wall Street Zen downgraded shares of MiNK Therapeutics to a “strong sell” rating in a report on Saturday, August 23rd. Zacks Research raised MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. HC Wainwright upgraded MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 target price for the company in a research report on Friday, August 15th. Finally, B. Riley raised shares of MiNK Therapeutics to a “strong-buy” rating in a report on Friday, July 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.